Startups developing vaccines, diagnostics, therapeutics and other infectious-disease technologies can access substantial non-dilutive R&D funding through the National Institute of Allergy and Infectious Diseases.

NIAID participates in the NIH SBIR and STTR programmes and supports commercial product development across infectious diseases, immunology, allergy and related fields.

For qualifying projects, current parent-announcement budgets can reach $700,000 in Phase I and $3 million in Phase II.

What Does NIAID Fund?

NIAID’s small-business portfolio covers three broad areas:

• Immune-system biology and host-microbe interactions;
• Diagnostic and prevention technologies;
• Treatment and cure strategies.

Current areas of particular interest include asthma and allergy, infectious-disease diagnostics, vaccines, vector-borne disease, prophylactic technologies, new therapeutics, persistent infections such as HIV and hepatitis B, improved drug formulations and implementation science.

The programme may therefore be relevant to companies developing everything from home infectious-disease tests to novel biologics.

How Much Funding Is Available?

NIAID’s limits under the current parent announcements are:

Phase I: up to $700,000.

Phase II: up to $3 million.

Not every project automatically qualifies for the highest amount.

Applicants should justify the requested budget based on actual development requirements and confirm whether their research area qualifies for budgets above statutory guidelines.

NIAID also participates in later-stage programmes.

Its current Phase IIB Strategic Breakthrough limit is $3 million, while its current CRP limit is $2 million.

SBIR Versus STTR

SBIR is generally appropriate where the company will lead and perform most of the R&D.

STTR requires collaboration with a qualifying nonprofit research institution.

Both mechanisms provide non-dilutive capital.

However, the clinical-trial rules are different.

Important Clinical Trial Restriction

NIAID accepts clinical trials through SBIR, but it currently does not accept clinical trials through the Parent STTR announcement.

NIAID also accepts clinical trials through Phase IIB but not under the current Parent CRP programme.

A company developing a vaccine or therapeutic that plans to perform human trials should therefore engage NIAID programme staff early.

Choosing the wrong funding mechanism could make an otherwise strong application non-responsive.

Who Can Apply?

Only eligible U.S. small businesses may receive NIAID SBIR/STTR awards.

NIAID has explicitly stated that an international company cannot directly apply for a small-business award.

Foreign founders interested in the programme therefore need to understand the federal U.S. company and ownership requirements before assuming that opening a simple American subsidiary is sufficient.

What Makes a Strong NIAID Proposal?

The scientific problem should be significant, but the application also needs a product-development story.

For a diagnostic, explain sensitivity, specificity, speed, cost, and usability compared with alternatives.

For a vaccine, describe the immunological rationale, development stage, and future regulatory pathway.

For therapeutics, address target validation, safety, manufacturing, competitive advantage and how the funded work reduces development risk.

NIAID reviewers should understand why the technology matters scientifically and why somebody will eventually use or purchase it.

When Can You Apply?

The September 2026 submission window has closed.

The next standard Parent SBIR and STTR deadline is January 5, 2027, followed by April 5.

Because registrations, scientific writing and budgets take substantial time, founders should begin preparation well before the submission month.

Review NIH institute-specific NIAID small-business priorities and rules

For infectious-disease and immunology companies, NIAID can provide the type of early technical funding private investors may be reluctant to provide before major clinical or regulatory risk has been removed.